Survey Among Healthcare Professionals Treating Patients With Metastatic Breast Cancer in Selected European Countries to Evaluate Their Knowledge on Management of Hyperglycemia When Using Alpelisib
Latest Information Update: 06 Jun 2024
At a glance
- Drugs Alpelisib (Primary)
- Indications Advanced breast cancer; Male breast cancer
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 31 May 2024 Planned End Date changed from 30 Sep 2024 to 30 Dec 2024.
- 31 May 2024 Planned primary completion date changed from 30 Sep 2024 to 30 Dec 2024.
- 03 Oct 2023 Planned End Date changed from 30 Jun 2023 to 30 Sep 2024.